6533b7ddfe1ef96bd1273ee5
RESEARCH PRODUCT
Can NF-κB Be Considered a Valid Drug Target in Neoplastic Diseases? Our Point of View
Monica NotarbartoloManuela LabbozzettaPaola Pomasubject
Drug targetAntineoplastic AgentsReviewCatalysisNF-κBdrug targetlcsh:ChemistryInorganic Chemistrychemistry.chemical_compoundNeoplasmsMDRmedicineBiomarkers TumorcancerAnimalsHumansMolecular Targeted TherapyPhysical and Theoretical Chemistrylcsh:QH301-705.5Molecular BiologySpectroscopyTriple-negative breast cancerbusiness.industryOrganic ChemistryNF-kappa BCancerMyeloid leukemiaNF-κBGeneral Medicinemedicine.diseaseComputer Science ApplicationsMultiple drug resistanceClinical trialCell Transformation Neoplasticlcsh:Biology (General)lcsh:QD1-999chemistryDrug Resistance NeoplasmHepatocellular carcinomaCancer researchSettore BIO/14 - FarmacologiaDisease Susceptibilitybusinessdescription
Multidrug resistance (MDR), of the innate and acquired types, is one of major problems in treating tumor diseases with a good chance of success. In this review, we examine the key role of nuclear factor-kappa B (NF-κB) to induce MDR in three tumor models characterized precisely by innate or acquired MDR, in particular triple negative breast cancer (TNBC), hepatocellular carcinoma (HCC), and acute myeloid leukemia (AML). We also present different pharmacological approaches that our group have employed to reduce the expression/activation of this transcriptional factor and thus to restore chemo-sensitivity. Finally, we examine the latest scientific evidence found by other groups, the most significant clinical trials regarding NF-κB, and new perspectives on the possibility to consider this transcriptional factor a valid drug target in neoplastic diseases.
| year | journal | country | edition | language |
|---|---|---|---|---|
| 2020-04-01 | International Journal of Molecular Sciences |